Non Viral Delivery Systems and LNP Platforms for Genetic Therapies Market Current Trends Analysis 2026 to 2035

Report Id: 3400 Pages: 180 Last Updated: 14 January 2026 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Market Segmentation:

Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Delivery Platform Type

  •  Lipid Nanoparticles (LNPs)
  •  Cell-Targeted LNPs (ctLNPs)
  •  Polymeric Nanoparticles
  •  DNA-Based Nanocarriers

Non Viral Delivery Systems and LNP Platforms for Genetic Therapies Market seg

Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Nucleic Acid Cargo

  •  mRNA
  •  siRNA
  •  miRNA
  •  Antisense Oligonucleotides (ASOs)

Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Application Area

  •  mRNA Therapeutics
  •  RNA Interference (RNAi) Therapies
  •  In Vivo Gene Editing
  •  Gene Replacement Therapies
  •  Protein Replacement via mRN

Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Target Tissue / Organ

  •  Liver
  •  Lung (Inhaled / Nebulized Delivery)
  •  Immune Cells
  •  Central Nervous System (CNS)

Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Route of Administration

  •  Intravenous (IV)
  •  Subcutaneous (SC)
  •  Intramuscular (IM)
  •  Inhalation / Pulmonary

Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market By Stage of Development

  •  Commercial / Approved Products
  •  Phase III
  •  Phase II

Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by End-User

  •  Biopharmaceutical Companies
  •  Gene Therapy Developers
  •  RNA Therapeutics Companies
  •  Academic & Research Institutes

By Region-

North America-

  •  The US
  •  Canada

Europe-

  •  Germany
  •  The UK
  •  France
  •  Italy
  •  Spain
  •  Rest of Europe

Asia-Pacific-

  •  China
  •  Japan
  •  India
  •  South Korea
  •  South East Asia
  •  Rest of Asia Pacific

Latin America-

  •  Brazil
  •  Argentina
  •  Mexico
  •  Rest of Latin America

Middle East & Africa-

  •  GCC Countries
  •  South Africa
  •  Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Snapshot

Chapter 4. Global Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Porter's Five Forces Analysis

4.7. Incremental Opportunity Analysis (US$ MN), 2026-2035

4.8. Competitive Landscape & Market Share Analysis, By Key Player (2026)

4.9. Use/impact of AI on Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Industry Trends

4.10. Global Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034

Chapter 5. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 1: By Delivery Platform Type, Estimates & Trend Analysis

5.1. Market Share by Delivery Platform Type, 2025 & 2035

5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Delivery Platform Type:

5.2.1. Lipid Nanoparticles (LNPs)

5.2.2. Cell-Targeted LNPs (ctLNPs)

5.2.3. Polymeric Nanoparticles

5.2.4. DNA-Based Nanocarriers

5.2.5. Extracellular Vesicles (Exosomes / EVs)

5.2.6. Hybrid Non-Viral Delivery Systems

Chapter 6. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 2: By Nucleic Acid Cargo,

Estimates & Trend Analysis

6.1. Market Share by Nucleic Acid Cargo, 2025 & 2035

6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Nucleic Acid Cargo:

6.2.1. mRNA

6.2.2. siRNA

6.2.3. miRNA

6.2.4. Antisense Oligonucleotides (ASOs)

6.2.5. Plasmid DNA

6.2.6. Circular RNA (circRNA / oRNA)

6.2.7. CRISPR/Cas Components (gRNA, mRNA, RNPs)

6.2.8. Base Editing & Prime Editing Payloads

Chapter 7. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 3: Application Area, Estimates & Trend Analysis

7.1. Market Share by Application Area, 2025 & 2035

7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Application Area:

7.2.1. mRNA Therapeutics

7.2.2. RNA Interference (RNAi) Therapies

7.2.3. In Vivo Gene Editing

7.2.4. Gene Replacement Therapies

7.2.5. Protein Replacement via mRNA

7.2.6. Cancer Genetic Therapies

7.2.7. Rare & Ultra-Rare Genetic Disorders

Chapter 8. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 4: Target Tissue / Organ, Estimates & Trend Analysis

8.1. Market Share by Target Tissue / Organ, 2025 & 2035

8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Target Tissue / Organ:

8.2.1. Liver

8.2.2. Lung (Inhaled / Nebulized Delivery)

8.2.3. Immune Cells

8.2.4. Central Nervous System (CNS)

8.2.5. Peripheral Nervous System

8.2.6. Muscle

8.2.7. Tumor / Solid Oncology Targets

8.2.8. Multi-Organ / Systemic Delivery

Chapter 9. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 5: By Route of Administration, Estimates & Trend Analysis

9.1. Market Share by Route of Administration, 2025 & 2035

9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Route of Administration:

9.2.1. Intravenous (IV)

9.2.2. Subcutaneous (SC)

9.2.3. Intramuscular (IM)

9.2.4. Inhalation / Pulmonary

9.2.5. Others (Intratumoral/Intrathecal)

Chapter 10. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 6: By Stage of Development, Estimates & Trend Analysis

10.1. Market Share by Stage of Development, 2025 & 2035

10.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Stage of Development:

10.2.1. Commercial / Approved Products

10.2.2. Phase III

10.2.3. Phase II

10.2.4. Phase I

10.2.5. Preclinical / Discovery Platforms

Chapter 11. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 7: By End-User, Estimates & Trend Analysis

11.1. Market Share by End-User, 2025 & 2035

11.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following End-User:

11.2.1. Biopharmaceutical Companies

11.2.2. Gene Therapy Developers

11.2.3. RNA Therapeutics Companies

11.2.4. Academic & Research Institutes

11.2.5. Strategic Platform Partners

Chapter 12. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 8: Regional Estimates & Trend Analysis

12.1. Global Tumour-Infiltrating Lymphocyte (TIL) Therapy Market, Regional Snapshot 2025 & 2035

12.2. North America

12.2.1. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

12.2.1.1. US

12.2.1.2. Canada

12.2.2. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035

12.2.3. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035

12.2.4. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035

12.2.5. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035

12.2.6. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035

12.2.7. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035

12.2.8. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035

12.3. Europe

12.3.1. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

12.3.1.1. Germany

12.3.1.2. U.K.

12.3.1.3. France

12.3.1.4. Italy

12.3.1.5. Spain

12.3.1.6. Rest of Europe

12.3.2. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035

12.3.3. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035

12.3.4. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035

12.3.5. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035

12.3.6. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035

12.3.7. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035

12.3.8. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035

12.4. Asia Pacific

12.4.1. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

12.4.1.1. India

12.4.1.2. China

12.4.1.3. Japan

12.4.1.4. Australia

12.4.1.5. South Korea

12.4.1.6. Hong Kong

12.4.1.7. Southeast Asia

12.4.1.8. Rest of Asia Pacific

12.4.2. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035

12.4.3. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035

12.4.4. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035

12.4.5. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035

12.4.6. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035

12.4.7. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035

12.4.8. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035

12.5. Latin America

12.5.1. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2022-2035

12.5.1.1. Brazil

12.5.1.2. Mexico

12.5.1.3. Rest of Latin America

12.5.2. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035

12.5.3. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035

12.5.4. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035

12.5.5. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035

12.5.6. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035

12.5.7. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035

12.5.8. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035

12.6. Middle East & Africa

12.6.1. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Mn) Estimates and Forecasts by country, 2022-2035

12.6.1.1. GCC Countries

12.6.1.2. Israel

12.6.1.3. South Africa

12.6.1.4. Rest of Middle East and Africa

12.6.2. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035

12.6.3. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035

12.6.4. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035

12.6.5. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035

12.6.6. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035

12.6.7. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035

12.6.8. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035

Chapter 13. Competitive Landscape

13.1. Major Mergers and Acquisitions/Strategic Alliances

13.2. Company Profiles

13.2.1. Acuitas Therapeutics

13.2.1.1. Business Overview

13.2.1.2. Key Product/Service

13.2.1.3. Financial Performance

13.2.1.4. Geographical Presence

13.2.1.5. Recent Developments with Business Strategy

13.2.2. Alnylam Pharmaceuticals

13.2.3. Arcturus Therapeutics

13.2.4. Beam Therapeutics

13.2.5. Code Biotherapeutics

13.2.6. CRISPR Therapeutics

13.2.7. CureAge Therapeutics

13.2.8. Editas Medicine

13.2.9. Evox Therapeutics

13.2.10. GenEdit

13.2.11. Genevant Sciences

13.2.12. Generation Bio

13.2.13. Genprex

13.2.14. Intellia Therapeutics

13.2.15. Moderna

13.2.16. NanoVation Therapeutics

13.2.17. Orna Therapeutics

13.2.18. ReCode Therapeutics

13.2.19. STRM.BIO

13.2.20. Vertex Pharmaceuticals 

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
8079
Security Code field cannot be blank!

Frequently Asked Questions

Non Viral Delivery Systems and LNP Platforms for Genetic Therapies Market is estimated to grow at a 16.1% CAGR during the forecast period for 2026 to 2035.

Acuitas Therapeutics, Alnylam Pharmaceuticals, Arcturus Therapeutics, Beam Therapeutics, Code Biotherapeutics, CRISPR Therapeutics, CureAge Therapeutics, Editas Medicine, Evox Therapeutics, GenEdit, Genevant Sciences, Generation Bio, Genprex, Intellia Therapeutics, Moderna, NanoVation Therapeutics, Orna Therapeutics, ReCode Therapeutics, STRM.BIO, Vertex Pharmaceuticals.

By Delivery Platform Type, Nucleic Acid Cargo, Application Area, Target Tissue, Route of Administration, Stage of Development, End-User are the key segments of the Non Viral Delivery Systems and LNP Platforms for Genetic Therapies Market

North America region is leading the Non Viral Delivery Systems and LNP Platforms for Genetic Therapies Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying